Most people have heard of incretin hormones, the gut-derived signals that drugmakers have turned into blockbuster obesity medicines over the past decade. Far fewer people have heard of amylin, a smaller hormone that the pancreas quietly releases alongside insulin every time you eat. A 2026 narrative review published in Diabetes, Obesity and Metabolism argues that amylin analogs could represent the next major category of obesity research compounds, offering a biological pathway that is meaningfully different from the incretin route.
The review, authored by Alhazmi Abdulhameed and colleagues, searched PubMed, clinical trial registries, company disclosures, and conference abstracts for every amylin-based therapy that had either been approved or reached human clinical development by April 2026. What they found was a field that has moved quickly from a modest proof-of-concept molecule to a pipeline of long-acting analogs and combination strategies that are now showing meaningful results in early trials.
This article walks through what amylin does in the body, why the first approved analog fell short, and what the newer generation of compounds is demonstrating in early-phase human studies.
What amylin does in the body
Amylin is a peptide hormone co-secreted with insulin from the beta cells of the pancreas. That timing is important. Because it is released in response to food intake, the body uses it as a mealtime signal rather than a fasting signal, and it influences several overlapping processes that together reduce how much food a person takes in and how quickly digestion proceeds.
The review identifies three main physiological actions. First, amylin slows gastric emptying, meaning food leaves the stomach more gradually after a meal. Second, it suppresses glucagon, a hormone that would otherwise raise blood glucose between meals. Third, and perhaps most interesting from a research perspective, it acts on central mechanisms in the brain to promote meal termination. In other words, it signals to the brain that enough food has been consumed. Researchers refer to this as a satiety or meal-termination effect.
These three actions work through different pathways than incretin hormones, which is one reason the review's authors argue that amylin analogs are not simply a redundant class. They address biological complexity by engaging a distinct set of receptors and circuits.
Pramlintide and the limits of first-generation analogs
The first amylin analog to reach approval was pramlintide, and the review treats it as an important proof of concept rather than a finished product. Pramlintide confirmed that mimicking amylin's actions in humans was safe and produced measurable effects on body weight and blood glucose control. That validation mattered enormously for the field.
The limitations, however, were real. The review notes that pramlintide's efficacy was modest compared with what researchers were beginning to see from incretin-based compounds. More practically, it required frequent dosing, which is a significant barrier to consistent use in any real-world or trial setting. These shortcomings pushed researchers toward a clear engineering goal: develop longer-acting versions that maintain the biological signal without requiring multiple daily injections.
That engineering challenge has now largely been addressed by the generation of analogs reviewed in the paper, most of which are designed for once-weekly or less-frequent dosing.
The newer long-acting analogs
The review covers six distinct long-acting amylin-based compounds that had entered human clinical development by early 2026: cagrilintide, eloralintide, petrelintide, MET-233i, ABBV-295, and AZD6234. While the paper does not report final efficacy numbers for all of them, the general finding across early-phase trials is that this generation demonstrates clinically meaningful weight loss with tolerability profiles that researchers describe as generally favorable.
Cagrilintide is the most studied of the group, partly because it has been evaluated both as a standalone compound and in combination with a glucagon-like peptide receptor agonist. The review highlights this dual role as particularly significant. In standalone trials, cagrilintide showed dose-dependent reductions in body weight. In combination trials, the pairing appeared to produce effects that exceeded what either compound achieved alone, a pattern researchers associate with complementary mechanisms acting through different pathways simultaneously.
The other analogs, including eloralintide and petrelintide, are earlier in development but represent important scientific diversity. Different structural modifications to the amylin backbone may produce different duration profiles, receptor selectivity, or tolerability characteristics, and the review suggests that researchers are actively exploring this space.
Combination strategies and the multi-pathway idea
One of the more notable themes in the review is the move toward combination therapy. The authors discuss two combination approaches in particular: cagrilintide paired with a semaglutide-class peptide, and a compound called zenagamtide, which appears to be a dual-acting molecule combining amylin and another hormonal signal in a single peptide.
The rationale for combinations is grounded in biology. Obesity is not driven by a single failed signal. It involves overlapping dysregulation of hunger hormones, satiety hormones, energy expenditure regulators, and metabolic feedback loops. A compound that only targets one pathway may produce good results in some people but leave others without adequate response. By stacking amylin-pathway signaling with incretin-pathway signaling, or by engineering molecules that activate multiple receptors, researchers are attempting to address more of that biological complexity at once.
Early data from the combination arms reviewed in the paper support this logic, showing weight reductions that the authors characterize as clinically meaningful. The review is careful to note that most of this evidence comes from early-phase trials, and larger, longer studies are needed to establish durability and longer-term safety profiles.
What early-phase trial data actually show
The review is a narrative synthesis rather than a meta-analysis, so it does not pool effect sizes into a single headline number. Instead, the authors describe a consistent directional finding: across the analogs and combinations reviewed, early-phase trials have generally shown meaningful reductions in body weight alongside acceptable tolerability.
Tolerability is a research consideration that the review discusses with some care. Amylin analogs have historically been associated with nausea, particularly when doses are titrated too quickly. The long-acting formulations appear to reduce that issue, possibly because slower absorption smooths out the peak concentration that tends to cause gastrointestinal side effects. The authors note that tolerability profiles across the newer compounds have been generally favorable in the trials reviewed, though they stop short of declaring any compound free of side effects.
The review also acknowledges that most of the evidence reviewed is from short-duration phase-1 and phase-2 studies. Phase-3 programs, which would establish whether these compounds work across diverse populations over longer periods, are either underway or planned for several of the agents discussed.
Why researchers see this as an evolving landscape
The review's conclusion is measured but optimistic. The authors position amylin-based therapies as a promising addition to an evolving treatment landscape, specifically because they address biological complexity through a pathway that is distinct from the incretin mechanisms that currently dominate obesity pharmacology research.
From a research perspective, the amylin field is interesting for several reasons. It offers a second major hormonal axis for study. It has already produced one approved molecule, establishing that the pathway is druggable. And the newer generation of long-acting analogs has cleared early safety hurdles while showing effects on body weight that justify further development. The combination data, still early, raise the possibility that pairing amylin-pathway and incretin-pathway compounds could produce additive or even synergistic effects, which would be a meaningful advance if confirmed in larger trials.
For readers curious about where peptide research is heading, the amylin story is a useful case study in how a hormone's basic physiology, understood for decades, can eventually be translated into a therapeutic research program through better molecular engineering and a clearer understanding of the central and peripheral circuits the hormone controls.
